Clearmind Medicine Embarks on Alcohol Use Disorder Solutions
Clearmind Medicine Makes Progress in Alcohol Treatment Clinical Trials
CMND-100 is shaping up to be a groundbreaking treatment option for millions worldwide suffering from Alcohol Use Disorder (AUD). This innovative therapy could provide much-needed relief in a field where options have long been limited. Clearmind Medicine Inc. (NASDAQ: CMND), a trailblazer in psychedelic-derived therapeutics, has recently announced a major milestone in its clinical trial journey.
First Patient Enrolled in Clinical Trial
In an exciting development, Clearmind has enrolled its first patient in a Phase I/IIa clinical trial for CMND-100, its proprietary MEAI-based oral drug candidate aimed at addressing AUD. Conducted at Yale School of Medicine’s Department of Psychiatry, this marks a significant step forward in the evaluation of CMND-100.
Study Focus and Goals
The clinical trial is set to assess the safety, tolerability, and pharmacokinetic profile of CMND-100. Importantly, it will also feature preliminary efficacy assessments to examine how effectively the treatment can help reduce alcohol cravings and consumption. These evaluations are crucial as they will provide the insights necessary for advancing toward a new, effective treatment option in the field.
Who Can Participate?
Eligible participants in the trial are adults aged between 18 to 60. This includes non-treatment-seeking individuals who engage in heavy binge drinking, as well as those diagnosed with AUD per DSM-5 criteria. All candidates must express a desire to reduce or quit drinking. The trial is reaching out to participants to fit these criteria, aiming to gather robust data that can potentially transform lives.
CEO Comments on the Development
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, expressed optimism regarding the trial, stating, "This advancement brings us one step closer to offering an innovative solution for those affected by AUD, a condition with significant unmet medical needs. The substance use disorder treatment market is experiencing exponential growth, valued at $35.1 billion in recent years, with projections reaching $60.2 billion soon. However, current treatment options often fall short due to their limited efficacy and undesired side effects. We believe CMND-100 has the potential to change this narrative, offering a reliable and effective solution for many."
Conducting the Clinical Trial
The clinical trial includes multiple prestigious sites, featuring Yale School of Medicine alongside Johns Hopkins University School of Medicine, with considerations for additional locations to expand its reach. Clearmind is dedicated to enhancing its intellectual property portfolio while advancing meaningful psychedelic-derived therapeutics to tackle pressing global health challenges.
Company Overview
Clearmind Medicine Inc. is revolutionizing the pharmaceutical biotech landscape with its focus on discovering and developing psychedelic-derived therapeutics. Their mission centers on tackling unmet health issues, with AUD being a primary focus. The company is committed to transforming research advancements into compared-to-market regulated medicines and supplements.
Intellectual Property and Future Prospects
Currently, Clearmind's robust intellectual property portfolio comprises nineteen patent families, which include 31 granted patents. The company continues to pursue additional patents where beneficial, showing a willingness to expand its intellectual property footprint significantly. This strategy supports its goal of ensuring a strong foundation for future developments and commercial success.
Listing and Contact Information
Clearmind’s shares are publicly traded on NASDAQ under the symbol “CMND” and on the Frankfurt Stock Exchange under “CWY0.” For inquiries related to investments or general information, individuals can find further details through the company’s official website or its investor relations contact.
Investor Relations
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries
Email: info@clearmindmedicine.com
Website: www.clearmindmedicine.com
Frequently Asked Questions
What is CMND-100?
CMND-100 is a proprietary oral drug candidate developed by Clearmind Medicine for treating Alcohol Use Disorder, utilizing a psychedelic-derived compound.
Where is the clinical trial being conducted?
The clinical trial is being conducted at multiple prestigious medical institutions, including Yale School of Medicine and Johns Hopkins University School of Medicine.
What are the eligibility criteria for participants?
Eligible participants are adults aged 18-60, whether treatment-seeking or non-treatment-seeking, who meet specific binge drinking criteria.
What does the trial aim to assess?
The trial aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CMND-100 in reducing alcohol cravings and consumption.
How can individuals get involved in the trial?
Interested individuals can check with the clinical trial sites or through the official Clearmind Medicine website for participation details and qualifications.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.